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[57] ABSTRACT 
The invention is directed to a method of highly purifying a 
polypeptide or other biological compounds from a contami-
nant by crystallization comprising contacting a mixture 
containing uncrystallized polypeptides and a contaminant 
with an exogenous nucleating agent, crystallizing the 
polypeptides, thereby forming at least one crystal of the 
polypeptide attached to the nucleating agent, the attached 
crystal being of a high purity, and at least one polypeptide 
crystal unattached to the nucleating agent, the unattached 
crystal being of a lower purity than the attached crystal, and 
separating the crystal attached to the nucleating agent from 
the crystal unattached to the nucleating agent. Also, the 
invention is directed to a method of purifying a polypeptide 
in a high purity and in a high yield from a contaminant by 
crystallization comprising contacting a mixture containing 
uncrystallized polypeptides and a contaminant with an exog-
enous nucleating agent that has a close lattice match to the 
polypeptide, crystallizing the polypeptides, thereby forming 
at least one crystal of the polypeptide attached to the 
nucleating agent, the attached crystal being of a high purity 
and produced in a high yield, and at least one crystal 
unattached to the nucleating agent, the unattached crystal 
being of a lower purity than the attached crystal, and 
separating the crystal attached to the nucleating agent from 
the crystal unattached to the nucleating agent. The invention 
is also directed to compositions comprising highly purified 
polypeptide or biological compound crystals and composi-
tions of highly purified polypeptides or biological com-
pounds. 
44 Claims, 3 Drawing Sheets 
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CRYSTALLIZATION AND PURIFICATION 
OF POLYPEPTIDES 
2 
attached crystal, and separating the crystal attached to the 
nucleating agent from the crystal unattached to the nucle-
ating agent. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
In another aspect, the invention provides for the product 
5 made by the methods of the invention. 
This invention relates generally to a method of purifying 
biological compounds or molecules, such as polypeptides, 
by crystallization. More particularly, the compounds can be 
purified to a significantly higher degree of purity than 
previously available techniques. In another embodiment, the 
present invention relates to crystallizing biological com-
pounds on nucleating agents with a close lattice match to the 
crystalline lattice of the biological compound to selectively 
obtain biological compound crystals of high purity in a high 15 
yield. 
In another aspect, the invention provides a composition 
consisting of at least one highly purified polypeptide crystal 
attached to an exogenous nucleating agent, wherein the 
polypeptide is not lysozyme, canavalin, concanavalin B, or 
10 beef liver catalase. 
In another aspect, the invention provides a composition 
consisting essentially of at least one highly purified polypep-
tide crystal attached to an exogenous nucleating agent, 
wherein the polypeptide is not lysozyme, canavalin, con-
canavalin B, or beef liver catalase. 
2. Background Art 
Crystallization of biological compounds, such as 
polypeptides, is important, both as one of the final separation 
In another aspect, the invention provides a composition 
comprising at least one highly purified polypeptide crystal 
attached to an exogenous nucleating agent, wherein the 
20 polypeptide is not lysozyme, canavalin, concanavalin B, or 
beef liver catalase. 
or purification steps in bioprocessing and for growing crys-
tals for basic scientific studies, such as structural analysis by 
X-ray diffraction. For example, improvements in protein 
purity are important to achieve more therapeutically accept-
able proteins for drug use and for facilitating or even 
permitting the study of proteins by, for example, X-ray 25 
diffraction for rational drug design. Traditional methods for 
crystallizing proteins (herein after referred to as 
polypeptides), such as by spontaneous crystallization 
wherein no nucleation agent is used, have resulted in high 
failure rates and high heterogeneity of any resulting crystals. 30 
The present invention provides techniques for obtaining 
biological compound crystals in higher purity than previ-
ously attained, or in a combination of a high purity in a high 
yield never before attainable, based on their attachment to an 
exogenous nucleating agent. 
In another aspect, the invention provides a composition 
consisting of a highly purified polypeptide crystal that has 
been separated from a nucleating agent, wherein the purity 
of the crystal is at least 99.85%. 
In another aspect, the invention provides a composition 
consisting essentially of a highly purified polypeptide crystal 
that has been separated from a nucleating agent, wherein the 
purity of the crystal is at least 99.85%. 
In another aspect, the invention provides a composition 
comprising a highly purified polypeptide crystal that has 
been separated from a nucleating agent, wherein the purity 
of the crystal is at least 99.85%. 
This invention, therefore, represents a new method of 
growing biological compound crystals, such as polypeptide 
crystals, of high purity, and solves a need in the art for 
producing crystals of high purity, and in one embodiment, in 
In another aspect, the invention provides a composition 
35 
consisting of a highly purified polypeptide that has been 
separated from a nucleating agent, wherein the purity of the 
polypeptide is at least 99.85%. 
a high purity and in a high yield. 40 
In another aspect, the invention provides a composition 
consisting essentially of a highly purified polypeptide that 
has been separated from a nucleating agent, wherein the 
purity of the polypeptide is at least 99.85%. 
SUMMARY OF THE INVENTION In another aspect, the invention provides a composition 
comprising a highly purified polypeptide that has been 
45 separated from a nucleating agent, wherein the purity of the 
polypeptide is at least 99.85%. 
In accordance with the purpose(s) of this invention, as 
embodied and broadly described herein, this invention, in 
one aspect, relates to a method of highly purifying a 
polypeptide from a contaminant by crystallization compris-
ing contacting a mixture containing uncrystallized polypep-
tides and a contaminant with an exogenous nucleating agent, 
crystallizing the polypeptides, thereby forming at least one 50 
crystal of the polypeptide attached to the nucleating agent, 
the attached crystal being of a high purity, and at least one 
polypeptide crystal unattached to the nucleating agent, the 
unattached crystal being of a lower purity than the attached 
crystal, and separating the crystal attached to the nucleating 55 
agent from the crystal unattached to the nucleating agent. 
The invention further provides a method of purifying a 
polypeptide in a high purity and in a high yield from a 
contaminant by crystallization comprising contacting a mix-
ture containing uncrystallized polypeptides and a contami- 60 
nant with an exogenous nucleating agent that has a close 
lattice match to the polypeptide, crystallizing the 
polypeptides, thereby forming at least one crystal of the 
polypeptide attached to the nucleating agent, the attached 
crystal being of a high purity and produced in a high yield, 65 
and at least one crystal unattached to the nucleating agent, 
the unattached crystal being of a lower purity than the 
In another aspect, the invention provides a method of 
highly purifying a biological compound from a contaminant 
by crystallization comprising contacting a mixture contain-
ing uncrystallized biological compounds and a contaminant 
with an exogenous nucleating agent, crystallizing the bio-
logical compounds, thereby forming at least one crystal of 
the biological compound attached to the nucleating agent, 
the attached crystal being of a high purity, and at least one 
biological compound crystal unattached to the nucleating 
agent, the unattached crystal being of a lower purity than the 
attached crystal, and separating the crystal attached to the 
nucleating agent from the crystal unattached to the nucle-
ating agent. 
In another aspect, the invention provides a method of 
purifying a biological compound in a high purity and in a 
high yield from a contaminant by crystallization comprising 
contacting a mixture containing uncrystallized biological 
compounds and a contaminant with an exogenous nucleating 
agent that has a close lattice match to the biological 
compound, crystallizing the biological compounds, thereby 
forming at least one crystal of the biological compound 
5,869,604 
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attached to the nucleating agent, the attached crystal being 
of a high purity and produced in a high yield, and at least one 
crystal unattached to the nucleating agent, the unattached 
crystal being of a lower purity than the attached crystal, and 
separating the crystal attached to the nucleating agent from 5 
the crystal unattached to the nucleating agent. 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "a highly purified 
crystal of the polypeptide" includes multiple highly purified 
crystals of the polypeptide. 
In one aspect, the invention relates to a method of highly 
purifying a polypeptide from a contaminant by crystalliza-
tion comprising contacting a mixture containing uncrystal-
lized polypeptides and a contaminant with an exogenous 
nucleating agent, crystallizing the polypeptides, thereby 
In another aspect, the invention provides a composition 
comprising at least one highly purified biological compound 
crystal attached to an exogenous nucleating agent, wherein 
the biological compound is not lysozyme, canavalin, con-
canavalin B, or beef liver catalase. 
In another aspect, the invention provides a composition 
comprising a highly purified biological compound crystal 
that has been separated from a nucleating agent, wherein the 
purity of the crystal is at least 99.85%. 
In yet another aspect, the invention provides a composi-
tion comprising a highly purified biological compound that 
has been separated from a nucleating agent, wherein the 
purity of the biological compound is at least 99.85%. 
Additional advantages of the invention will be set forth in 
part in the description which follows, and in part will be 
obvious from the description, or may be learned by practice 
of the invention. The advantages of the invention will be 
realized and attained by means of the elements and combi-
nations particularly pointed out in the appended claims. It is 
to be understood that both the foregoing general description 
and the following detailed description are exemplary and 
explanatory only and are not restrictive of the invention, as 
claimed. 
The accompanying figures, which are incorporated in and 
constitute a part of this specification, illustrate several 
embodiments of the invention and together with the 
description, serve to explain the principles of the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the purity oflysozyme crystals grown in the 
absence of exogenous mineral nucleating agents (control) 
compared to lysozyme crystals attached to exogenous min-
eral nucleating agents (mineral substrate). 
FIG. 2 shows the purity oflysozyme crystals grown in the 
absence of exogenous mineral nucleating agents (control) 
compared to lysozyme crystals grown in the presence of 
exogenous mineral nucleating agents but not attached to 
exogenous mineral nucleating agents (mineral substrate). 
FIG. 3 shows the yield of recovered protein from crystals 
attached to exogenous mineral nucleating agents compared 
to crystals grown in the absence of exogenous mineral 
nucleating agents (mineral substrate). 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
10 forming at least one crystal of the polypeptide attached to the 
nucleating agent, the attached crystal being of a high purity, 
and at least one polypeptide crystal unattached to the nucle-
ating agent, the unattached crystal being of a lower purity 
than the attached crystal, and separating the crystal attached 
15 to the nucleating agent from the crystal unattached to the 
nucleating agent. 
The invention further provides a method of purifying a 
polypeptide in a high purity and in a high yield from a 
contaminant by crystallization comprising contacting a mix-
20 ture containing uncrystallized polypeptides and a contami-
nant with an exogenous nucleating agent that has a close 
lattice match to the polypeptide, crystallizing the 
polypeptides, thereby forming at least one crystal of the 
polypeptide attached to the nucleating agent, the attached 
25 crystal being of a high purity and produced in a high yield, 
and at least one crystal unattached to the nucleating agent, 
the unattached crystal being of a lower purity than the 
attached crystal, and separating the crystal attached to the 
nucleating agent from the crystal unattached to the nucle-
30 ating agent. 
In another aspect, the invention provides for the product 
made by the methods of the invention. 
In another aspect, the invention provides a composition 
35 consisting of at least one highly purified polypeptide crystal 
attached to an exogenous nucleating agent, wherein the 
polypeptide is not lysozyme, canavalin, concanavalin B, or 
beef liver catalase. 
In another aspect, the invention provides a composition 
40 consisting essentially of at least one highly purified polypep-
tide crystal attached to an exogenous nucleating agent, 
wherein the polypeptide is not lysozyme, canavalin, con-
canavalin B, or beef liver catalase. 
In another aspect, the invention provides a composition 
45 comprising at least one highly purified polypeptide crystal 
attached to an exogenous nucleating agent, wherein the 
polypeptide is not lysozyme, canavalin, concanavalin B, or 
beef liver catalase. 
In another aspect, the invention provides a composition 
50 
consisting of a highly purified polypeptide crystal that has 
been separated from a nucleating agent, wherein the purity 
of the crystal is at least 99.85%. The present invention may be understood more readily by 
reference to the following detailed description of preferred 
embodiments of the invention and the Example included 55 
therein and to the Figures and their previous and following 
description. 
In another aspect, the invention provides a composition 
consisting essentially of a highly purified polypeptide crystal 
that has been separated from a nucleating agent, wherein the 
purity of the crystal is at least 99.85%. 
In another aspect, the invention provides a composition 
comprising a highly purified polypeptide crystal that has 
been separated from a nucleating agent, wherein the purity 
of the crystal is at least 99.85%. 
Before the present compounds, compositions and meth-
ods are disclosed and described, it is to be understood that 
this invention is not limited to specific methods, specific 60 
exogenous nucleating agents, or specific polypeptides, or 
other specific crystallizable compounds, as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
embodiments only and is not intended to be limiting. 
In another aspect, the invention provides a composition 
consisting of a highly purified polypeptide that has been 
separated from a nucleating agent, wherein the purity of the 
65 polypeptide is at least 99.85%. 
It must be noted that, as used in the specification and the 
appended claims, the singular forms "a," "an" and "the" 
In another aspect, the invention provides a composition 
consisting essentially of a highly purified polypeptide that 
5,869,604 
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has been separated from a nucleating agent, wherein the 
purity of the polypeptide is at least 99.85%. 
6 
opposed to spontaneous nucleation of a polypeptide or any 
other compound that is being crystallized. 
In another aspect, the invention provides a composition 
comprising a highly purified polypeptide that has been 
separated from a nucleating agent, wherein the purity of the 5 
polypeptide is at least 99.85%. 
The term "exogenous" nucleating agent is used herein to 
describe any foreign material, or a material of a different 
type, added to the crystallization mixture to induce crystal-
lization of a polypeptide, but which does not include a 
Highly purified polypeptide crystals can be obtained by 
any of the methods of the invention. 
In another aspect, the invention provides a method of 
highly purifying a biological compound from a contaminant 
by crystallization comprising contacting a mixture contain-
ing uncrystallized biological compounds and a contaminant 
with an exogenous nucleating agent, crystallizing the bio-
logical compounds, thereby forming at least one crystal of 
the biological compound attached to the nucleating agent, 
the attached crystal being of a high purity, and at least one 
biological compound crystal unattached to the nucleating 
agent, the unattached crystal being of a lower purity than the 
attached crystal, and separating the crystal attached to the 
nucleating agent from the crystal unattached to the nucle-
ating agent. 
In another aspect, the invention provides a method of 
purifying a biological compound in a high purity and in a 
high yield from a contaminant by crystallization comprising 
contacting a mixture containing uncrystallized biological 
compounds and a contaminant with an exogenous nucleating 
agent that has a close lattice match to the biological 
compound, crystallizing the biological compounds, thereby 
forming at least one crystal of the biological compound 
attached to the nucleating agent, the attached crystal being 
of a high purity and produced in a high yield, and at least one 
crystal unattached to the nucleating agent, the unattached 
crystal being of a lower purity than the attached crystal, and 
separating the crystal attached to the nucleating agent from 
the crystal unattached to the nucleating agent. 
In another aspect, the invention provides a composition 
comprising at least one highly purified biological compound 
crystal attached to an exogenous nucleating agent, wherein 
the biological compound is not lysozyme, canavalin, con-
canavalin B, or beef liver catalase. 
In another aspect, the invention provides a composition 
comprising a highly purified biological compound crystal 
that has been separated from a nucleating agent, wherein the 
purity of the crystal is at least 99.85%. 
In yet another aspect, the invention provides a composi-
tion comprising a highly purified biological compound that 
has been separated from a nucleating agent, wherein the 
purity of the biological compound is at least 99.85%. 
In this specification and in the claims which follow, 
reference will be made to a number of terms which shall be 
defined to have the following meanings: 
It is to be understood that reference to polypeptide crys-
tallization in this invention applies equally as well to other 
biological molecules or compounds and recitation herein of 
the more specific "polypeptide" is not intended to be limit-
ing as it also includes the broader category of biological 
compounds for all aspects of this invention. 
The term "mixture" is a term familiar to one of ordinary 
skill in the art and is used herein to describe, for example, 
non-solutions, solutions, emulsions, suspensions, 
concentrates, slurries, and the like. 
The term "nucleating agent" is a term familiar to one of 
ordinary skill in the art and is used herein to describe any 
material where a solid interface causes a reduction in the 
critical supersaturation required for crystallization as 
crystalline seed of the polypeptide itself. 
The term "heterogeneous nucleation" is a term familiar to 
one of ordinary skill in the art and is used herein to describe 
10 nucleation of a polypeptide or other compound being crys-
tallized by initiating crystallization on a solid interface in the 
crystallization mixture. 
15 
The term "epitaxial substrate" is a term familiar to one of 
ordinary skill in the art and is used herein to describe a type 
of heterogeneous nucleation where the crystallographic ori-
entation of the polypeptide or other compound being crys-
tallized is restricted to one or few possibilities by the 
crystallographic orientation of the substrate surface. 
20 
The term "crystalline lattice" is a term familiar to one of 
ordinary skill in the art and is used herein to describe a 
regularly spaced array of points that represents the structure 
of the crystal. Crystals are composed of groups of atoms 
repeated at regular intervals in three dimensions with the 
25 
same orientation. Each such group of atoms is replaced by 
a representative point; the collection of points so formed is 
the lattice of the crystal. 
The term "lattice match" is used herein to describe an 
areal lattice match between the area of the crystalline lattice 
30 of the exogenous nucleating agent and the area of the 
crystalline lattice of the polypeptide or other compound 
being crystallized. The two interacting lattices do not have 
to be exact fits to be a "close" lattice match as defined herein. 
The linear lattice dimension of one crystal face of the unit 
35 cell may be integral multiples of the dimensions on the other 
when calculating the areal lattice match. 
The term "unit cell" is a term familiar to one of ordinary 
skill in the art and is used herein to describe the smallest unit 
of the lattice that displays the symmetry of the crystalline 
40 lattice. 
The term "crystal" as used herein is defined to mean one 
or more single crystals. For example, a single nucleating 
agent may have one or several attached polypeptide crystals. 
The term "majority" as used herein is defined as greater 
45 than 50% of the crystals. 
As used herein, the term "polypeptide" is intended to 
include any peptides, oligopeptides, polypeptides, proteins, 
protein segments, protein domains, enzymes, enzyme 
segments, enzyme domains, and the like, that are crystalli-
50 zable. This term is intended to include polypeptide com-
pounds of the same species, or polypeptide compounds of 
more than one species. Some examples of polypeptides that 
can be used in this invention include, but are not limited to, 
chicken egg white lysozyme, albumin, catalase, canavalin, 
55 concanavalin B, vicillin, insulin, pepsin, pyruvate kinase, 
creatine kinase, lactate dehydrogenase, and selenomethion-
ine. The polypeptide is not restricted to a particular size. The 
polypeptide may be of about 2 amino acids or more, as long 
as it is crystallizable. Additionally, the polypeptide may be 
60 modified. Examples of such modifications include, but are 
not limited to, post-translational methylation, acetylation, 
phosphorylation, and glycosylation. Chemical derivatives of 
polypeptides can also be used in this invention. Such chemi-
cal derivatives may include polypeptides attached to other 
65 compounds through glutaraldehyde or carbodiimide cross-
linking, polypeptides conjugated to a fiuorochrome or other 
moieties, or polypeptides containing modified amino acid 
5,869,604 
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periodic array of chemical groups exposed on the surface of 
the nucleating agent to effectively concentrate and organize 
the crystallizing compounds into an ordered and periodic 
layer. This initial restricted and organized order then is 
residues. Additionally the polypeptides may include those 
polypeptides together with a ligand or cofactor. Specific 
examples of this include, but are not limited to, myoglobin 
together with its associated iron atom, and coenzyme B12 
with its associated cobalt atom. 
Additionally, other molecules or compounds may be used 
in this invention as well as polypeptides. A skilled practi-
tioner in the art will readily appreciate that other compounds 
may be crystallized and purified using the disclosed meth-
ods. For example, these other compounds may include, but 
are not limited to, amino acids, nucleic acid molecules such 
5 propagated in the third dimension as more and more crys-
tallizing compounds are added by normal crystal growth 
mechanisms. Not wishing to be bound by theory, it is 
believed that nucleation of a polypeptide having a close 
lattice match to the nucleating agent relates to epitaxial 
as tRNA and hybrids between different types of nucleic 
acids, mono- and polyclonal antibodies, hormones, 
nucleotides, nucleosides, and toxins, nucleic acid/drug 
complexes, nucleic acid/polypeptide complexes, histones, 
ribosomes, and viruses. Specific examples include, but are 
not limited to, tobacco mosaic virus, poliovirus, and cytome-
galovirus. 
10 nucleation. These terms, however, are not equivalent. Also 
not wishing to be bound by theory, it is also believed that a 
close lattice match may be a prerequisite for epitaxial crystal 
growth, but crystals can exhibit epitaxial growth on exog-
enous nucleating agents that do not have a close lattice 
15 match to the polypeptide. 
The present invention discloses a method of obtaining 
polypeptide crystals of high purity by using an exogenous 
nucleating agent that may optionally have a close lattice 
match, or obtaining polypeptide crystals of high purity and The present invention provides for crystallizing polypep-
tides or other biological compounds on an exogenous nucle-
ating agent. Crystallization initiates with a nucleation phase, 
20 high yield by using an exogenous nucleating agent that has 
a close lattice match to the polypeptide. The lattice match is 
determined by the areal dimensions of the two crystals. This 
areal lattice match calculation is well known to one of skill 
in the art. See, e.g., McPherson, A and Shlichta, P. J. 
i.e. the formation of the first ordered aggregates. This 
formation of the first ordered aggregates, in nucleations 
other than spontaneous nucleation, is achieved by the pres-
ence of a solid interface in the crystalline mixture, which is 25 
referred to herein as the exogenous nucleating agent. This 
surface causes a reduction in the critical supersaturation (or 
supercooling) required for crystal nucleation. Any such 
agent that achieves the aforementioned reduction in the 
critical supersaturation (or supercooling) can be used in the 30 
present invention. Such exogenous nucleating agents 
include, but are not limited to, minerals, transition metal ions 
such as copper and lead, highly absorbent structures such as 
zeolites, preformed crystal seeds of amino acids, and pre-
formed crystal seeds of polypeptides other than the polypep- 35 
tide being crystallized. 
More than a single exogenous nucleating agent can be 
present in a single crystallization mixture. For example, a 
single crystallization mixture can contain many exogenous 40 
nucleating agents of the same type, or even of different 
types. Each exogenous nucleating agent present in a crys-
tallization mixture can have a single polypeptide crystal 
attached to it, or have multiple crystals attached to it. 
Facilitation of the growth of protein crystals by 
heterogeneous/epitaxial nucleation. J. Crystal Growth 
85:206-214 (1987). To calculate the areal lattice match 
between two crystalline surfaces, the X and Y linear dimen-
sions of a lattice surface of a polypeptide or other biological 
compound are compared on an area basis to the correspond-
ing X' and Y' linear dimensions of the exogenous nucleating 
agent. Specifically, the percent mismatch is calculated as 
follows: 
((the lattice area of the exogenous nucleating agent minus 
the lattice area of the polypeptide or other biological 
compound), divided by the lattice area of the polypep-
tide or other biological compound), multiplied by 100, 
yields a figure. The absolute value of that figure is the 
percent areal lattice mismatch between the two lattice 
surfaces. One hundred minus this mismatch figure, 
therefore, is the percent areal lattice match between the 
two lattice surfaces. 
The lattice dimensions of the crystal face on the nucle-
ating agent and on the biological compound can be integral 
45 multiples of one another. This is taken into account in the 
lattice match calculation. This calculation is not applicable 
to those exogenous nucleating agents that do not have a 
definable unit cell; therefore, they do not have a lattice 
Once mixed with the exogenous nucleating agent, the 
crystallization of the polypeptide or other compound can be 
through any number of crystallization procedures that are 
well known in the art. For example, detailed laboratory 
procedures are published which present actual methods for 
crystallizing biological compounds. Typically, crystalliza- 50 
tion involves lowering the temperature of the mixture con-
taining the polypeptide or increasing the concentration of the 
polypeptide in the mixture by, for example, removing sol-
vent from the mixture containing the polypeptide through 
vapor diffusion. Other crystallization techniques include, but 
are not limited to, batch crystallization, dialysis, gel 
crystallization, and liquid bridge crystallization. General 
crystallization conditions are set forth, for example, in 
Crystallization of Nucleic Acids and Proteins: A Practical 
Approach, ed. A Ducruix and R. Giege, Oxford University 
Press, New York, 1992. 
match to the biological compound crystal. 
In one embodiment, the present invention provides for 
purification of polypeptides by crystallization of a polypep-
tide using a nucleating agent with a close lattice match to the 
lattice of the polypeptide. The lattice match does not have to 
be an exact fit to be within the scope of this invention. In 
55 particular, the areal lattice match between the respective X 
and Y coordinates of the nucleating agent and the polypep-
tide is preferably at least 80% of each other, more preferably 
within at least 85% of each other, even more preferably 
within at least 90% of each other, even more preferably 
60 within at least 95% of each other, and even more preferably 
within at least 98% of each other. The lattice dimensions for 
Epitaxial nucleation is a type of nucleation wherein the 
crystallographic orientation of the crystallizing material is 
restricted to one or few possibilities by the crystallographic 
structure of the nucleating substrate surface. This restricted 65 
growth orientation of the polypeptide on the nucleating 
surface is presumably a consequence of the ability of the 
calculating the lattice area for a number of substrates, 
including mineral substrates, is readily obtainable to one 
skilled in the art. 
The exogenous nucleating agent with a close lattice match 
can be any crystalline material that may serve as a nucleating 
agent and which has a close lattice match to the lattice of a 
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polypeptide. These include, but are not limited to, crystalline 
forms of minerals, transition metal ions such as copper and 
lead, highly absorbent structures such as zeolites, preformed 
crystal seeds of amino acids, preformed crystal seeds of 
polypeptides other than the polypeptide being crystallized, 5 
other biological compounds, and other like crystals. 
ating agent. Other methods of separating a crystal attached 
to a nucleating agent from a crystal unattached to a nucle-
ating agent will be apparent to a skilled practitioner in the 
art. 
Additionally, crystals that are attached to a nucleating 
agent may be separated from that nucleating agent through 
any number of means. For example, the highly purified 
polypeptide crystal may be physically separated, either in 
part or in whole, from the nucleating agent by detaching the 
crystal from the nucleating agent, by for example, shearing, 
or by dissolving the purified polypeptide crystal in a suitable 
Typical minerals that can be used include, but are not 
limited to, apophyllite, lepidolite, topaz, galena, quartz, and 
microcline, which can be found, for example, in Lattice 
Structure of Minerals, L. G. Berry, et al., in Mineralogy, 2nd 10 
Ed., W. H. Freeman and Co., San Francisco, Calif. (1983), 
which is herein incorporated by reference, for all its teach-
ings and for all the specific teachings of typical minerals. 
Alternatively, mineral surfaces can be artificially synthe-
sized which have a pre-designed lattice structure. These 15 
artificial mineral substrates can be created to fulfill a general 
purpose, or alternatively, to match with a specific protein 
lattice. 
solvent and then removing this solubilized polypeptide from 
the nucleating agent, thereby separating the two. 
In one embodiment, the separation of this invention 
achieves separating the polypeptide crystal attached to the 
nucleating agent from the other components in the crystal-
lization mixture, so that one may have possession of a highly 
purified crystal attached to the nucleating agent apart from 
contaminants, from any other components of the crystalli-An example of a non-mineral nucleating agent exhibiting 
close lattice match characteristics to a material being crys-
tallized is a nucleic acid sequence complementary to the 
nucleic acid being crystallized. This intramolecular 
coupling, or hybridization, at the molecular level can lead to 
intramolecular coupling at the crystalline level after crys-
tallization of the initial hybrid. One skilled in the art will 
recognize that the precise binding between the two nucleic 
acid sequences will serve as a template for subsequent 
additional crystal growth on the nucleic acid hybrid. 
Another example of a nucleating agent with close lattice 
match characteristics is the specific binding between a 
specific antibody and its antigen, or vice versa. This intramo-
lecular coupling at the molecular level can lead to intramo-
lecular coupling at the crystalline level after crystallization 
of the initial hybrid. 
One skilled in the art will readily appreciate the number 
of biological compounds that may be used in the disclosed 
method. Lattice characteristics of these compounds can be 
obtained from reference materials or by direct measurement. 
Similarly, the lattice dimensions of proteins are readily 
obtainable to one in the art. One such example of a source 
for this information can be found in Lattice Structure of 
Proteins, NIST/NASNCARB Biological Macromolecule 
Crystallization Database, Ver. 3.0, (March 1994), which is 
herein incorporated by reference, for all its teachings and for 
all the specific teachings of typical proteins. 
Once the polypeptide is crystallized, there results a mix-
ture of crystal(s) attached to the nucleating agent(s) and 
unattached crystals. It is beneficial to separate the attached 
crystals into an isolated format away from the unattached 
crystals so that a composition of attached crystals substan-
tially free of unattached crystals is provided. Any number of 
methods may be used to separate a crystal, a plurality of 
crystals, or a majority of crystals attached to the nucleating 
agent from the unattached crystals. This achieves the isola-
tion of the pure crystals, which are attached to the nucleating 
agent, from the impure crystals, which are unattached. For 
example, the attached crystal may be isolated by hand 
selection or by sieving. Alternatively, the attached crystal 
may be isolated from an unattached crystal based on a 
magnetic property of the nucleating agent or isolating the 
nucleating agent with an attached crystal from the crystal-
lization mixture based upon its mass, for example through 
density separation by differential centrifugation. An addi-
tional separation technique may include attaching the nucle-
ating agent to a solid support and removing the solid support 
and its associated nucleating agent from the crystallization 
mixture after the polypeptide has crystallized on the nucle-
20 zation mixture, and from any crystals that crystallized unat-
tached to a nucleating agent. In a further embodiment, by 
removing the nucleating agent from crystals to which it is 
attached, the polypeptide crystal is separated and isolated 
from the nucleating agent as well as from the other compo-
25 nents in the crystallization mixture, so that one may have 
possession of a highly purified polypeptide apart from 
contaminants, from any other components of the crystalli-
zation mixture, from any crystals that crystallized unat-
tached to a nucleating agent, and from the nucleating agent 
30 to which the highly purified polypeptide crystallized. 
Moreover, one may convert the polypeptide crystal to a 
non-crystalline form, thereby achieving a separation or 
isolation of highly pure polypeptide. Thus, one may have 
possession of a highly purified polypeptide crystal or a 
35 highly purified polypeptide that may be used in later analy-
ses or for other uses. 
In this invention, the crystals attached to the nucleating 
agent are of significantly higher purity, that is, they have a 
lower amount of contaminants, than crystals that are unat-
40 tached to a nucleating agent or those which nucleate spon-
taneously. In preferred embodiments, the term "high purity" 
relates to a level of purity not before repeatable through 
conventional polypeptide crystallization. In the crystalliza-
tion art, a common technique for determining the "quality" 
45 of a crystal is often limited to visual inspection of crystals to 
determine whether they are morphologically correct, such as 
whether they have distinct and symmetrical faces and edges, 
whether the crystal has structural cracks, and whether the 
crystal is clear rather than cloudy or mottled. Thus, the use 
50 of the term high quality in the art is not the same as the use 
of the term "high purity" as used herein. A major technique 
used in the past to determine the purity of a polypeptide 
crystal is the X-ray diffraction pattern these crystals yield 
when subjected to x-ray diffraction analysis. This technique, 
55 however, does not yield a quantitative value of crystal purity 
but rather a qualitative assessment since the X-ray pattern 
observed only allows the detection of high impurity levels 
that make a diffraction difference at the unit cell dimensions. 
Once the polypeptide is crystallized on a nucleating agent 
60 and separated from crystals unattached to the nucleating 
agent, any number of methods of biochemical analysis 
typically used in the art can give specific information about 
the actual content of the crystals. For example, the polypep-
tide crystals can be resolubilized and then subjected to 
65 qua n tit at iv e an a 1ytica1 techniques such as 
spectrophotometry, electrophoresis, isoelectric focusing, 
sequencing, ultrafiltration, dialysis, chromatography based 
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on mass, charge, or affinity, assay kinetics, or combinations 
of these techniques, and the like. 
Accordingly, the present invention can achieve a polypep-
tide crystal that is at least 99.65% pure, more preferably at 
least 99.70% pure, more preferably at least 99.75% pure, 5 
more preferably at least 99.80% pure, more preferably at 
least 99.85% pure, more preferably at least 99.90% pure, 
more preferably at least 99.92% pure, more preferably at 
least 99.94% pure, more preferably at least 99.96% pure, 
more preferably at least 99.97% pure, more preferably at 10 
least 99.98% pure, and more preferably at least 99.99% 
pure. Purity, as used herein, relates to any contaminant that 
the polypeptide is being purified and isolated away from and 
depends on the specifics of the crystallization itself The 15 
particular contaminants will be apparent to a skilled practi-
tioner in the art. Of course, the presence of the attached 
nucleating agent is not considered in the purity calculation. 
The purity of a crystallized polypeptide relates to the con-
tamination of the desired polypeptide in the crystal by a 20 
different or unrelated polypeptide in the same crystal, or by 
an undesirable compound or molecule unrelated to the 
polypeptide. For example, a crystal that has both lysozyme 
and ovotransferrin in the same crystal constitutes a crystal of 
lysozyme that is contaminated with ovotransferrin, or a 25 
ovotransferrin crystal that is contaminated with lysozyme, 
depending on the desired crystallized polypeptide. 
Alternatively, a contaminant of a polypeptide crystal may be 
a nucleic acid that was present in the mixture containing the 
polypeptide being crystallized. A contaminant in the mixture 30 
can comprise more than a single type species of a contami-
nant. For example, a crystallization mixture may contain two 
or more types of contaminants. For another example, a 
mixture may contain several different species of polypep-
tides and other contaminants in the same mixture, where a 35 
specific species of polypeptide or more than one specific 
species of polypeptide is being crystallized on their respec-
tive nucleating agent. Alternatively, a mixture may contain 
more than one polypeptide species, nucleic acids, 
detergents, etc., in addition to the polypeptide species being 40 
crystallized. Other contaminants include, but are not limited 
to amino acids, nucleotides, ions, salts, carbohydrates, 
precipitants, cellular components such as micro and macro-
molecular structures, and the like. 
As used herein, the term "yield" relates to the mass of the 45 
purer form of the polypeptide recovered from the crystalli-
zation mixture. In a crystallization mixture which includes 
an exogenous nucleating agent of this invention, yield is the 
total mass of polypeptide crystal obtained from the crystal-
lization procedure that is attached to the nucleating agent 50 
over the total mass of polypeptide in the crystallization 
mixture. If the crystallization reaction occurs without an 
exogenous nucleating agent, the yield is the total mass of 
crystallized polypeptide over the total mass of polypeptide 
in the crystallization mixture. The term "high yield" then 55 
relates to a comparison of these two yields. For example, the 
control yield minus the yield for crystals attached to an 
exogenous nucleating agent multiplied by 100 and then 
divided by the control yield gives a yield of the crystals 
attached to the nucleating agent as a percent deviation from 60 
the control yield. The term "high yield" applies to (1) a 
polypeptide crystallization in the presence of an exogenous 
nucleating agent where this percent deviation relative to the 
control is less than 22% if the yield is lower with an 
exogenous nucleating agent than the control, or (2) any yield 65 
with an exogenous nucleating agent which is higher than the 
control yield. 
12 
Utility 
The present invention has many useful and practical 
utilities as noted herein. For example, the present invention 
provides for a method of crystallizing polypeptides in high 
purity. These highly purified polypeptide crystals may be 
used in X-ray diffraction studies for polypeptide structural 
analysis in rational drug design. Alternatively, the present 
invention provides a method for highly purifying polypep-
tide crystals whose polypeptide may later be used as a drug. 
The following example is put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how the purified polypeptides claimed herein 
are made and evaluated, and is intended to be purely 
exemplary of the invention and is not intended to limit the 
scope of what the inventors regard as their invention. Efforts 
have been made to ensure accuracy with respect to numbers 
(e.g., amounts, temperature, etc.) but some errors and devia-
tions should be accounted for. Unless indicated otherwise, 
parts are parts by weight, temperature is in ° C. and pressure 
is at or near atmospheric. 
EXAMPLE 
Analysis of Chicken Egg White Lysozyme 
Crystallized on Various Exogenous Mineral 
Substrates 
Reagents and Substrates. Experiments were conducted 
using chicken-white lysozyme (Sigma, Grade I, Lot 
111H7010, MW-14,600). The lysozyme was crystallized 
three times, dialyzed, and lyophilized by the supplier. The 
Sigma product is 95% protein with a balance of buffer salts 
as sodium acetate and sodium chloride and 0.5 to 2.5% 
albumin. 
Amounts of lysozyme were weighed with an accuracy of 
0.1 mg using an electronic balance (Ohaus, AP250D). The 
lysozyme was then dissolved in a sodium acetate buffer. 
(O.lM, pH 4.0) The stock lysozyme solution was prepared at 
a concentration of 50 mg/ml. The solution was then divided 
into 2 ml aliquots and stored at 17° C. until needed. The 
nucleating agents chosen for this study were magnetite, 
lepidolite, topaz, NC-apophyllite (a non-cleavable surface of 
apophyllite that does not have a lattice match to lysozyme), 
and apophyllite. (Purchased from Ward's Natural Science 
Company, Rochester, N.Y.). The areal lattice match between 
lysozyme and apophyllite was calculated as follows: 
The two linear lattice dimensions for lysozyme are 79.1 A 
and 37.9 A, the two linear lattice dimensions for 
apophyllite are 38.1 A(12.7Ax3) and 79 A(15.8Ax5). 
~(7_9_A_x_3_8_.1~A~" l_-_(~7-9._1_A._x_3_7_.9_A~)- ~ 0.40% areal mismatch 
(79.lA x 37.9A) 
The areal mismatch of the other exogenous nucleating 
agents were calculated in a similar manner. Relative to the 
areal crystalline lattice of lysozyme, the percent areal mis-
match of the areal lattice of apophyllite, topaz, and 
lepidolite, are 0.40%, 9.6%, and 20.8%, respectfully. Thus, 
their lattice match is 99.60%, 90.40%, and 79.20%, respect-
fully. Magnetite and NC-apophyllite do not have defined 
unit cells and lattice dimensions; therefore, these areal lattice 
mismatches cannot be calculated, and so, these minerals do 
not have a lattice match. Thus, these minerals represent 
nucleating agents whose areal mismatch clearly exceed 15% 
to that of lysozyme. These substrates were cleaved for the 
desired surface area (surface diameter approximately 850 
µm) and then sieved. A typical crystallization well contained 
one mineral particle. 
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Lysozyme was crystallized by the vapor diffusion method 
on plates (Product number 7220, Corning, Corning, N.Y.) 
(General discussion of the vapor diffusion technique are set 
forth in Crystallization of Nucleic Acids and Proteins: A 
Practical Approach, ed. A Ducruix and R. Giege, Oxford 5 
University Press, New York, 1992). Each depression plate 
consisted of nine crystallization wells. The depression plates 
were siliconized with Sigmacote (Sigma # SL-2) prior to 
beginning crystallization trials. The pre-crystallization solu- 10 
tion consisted of lysozyme, ovotransferrin (Sigma Chemical 
Co., Prod. No. C-0755, Lot No. 107F8020) (5% of total 
protein), sodium acetate buffer (O.lM) at pH 4.0, and 2.5 wt 
% NaCl as precipitating agent in high purity water (HPLC 
grade, J. T. Baker Prod. No. 4218-03). All pre-crystallization 15 
solutions were passed through a 0.2 µm pore filter (Nalgene) 
and used immediately. Each well of the crystallization plate 
was supplied with 150 µl of the pre-crystallization solution. 
Protein Crystallization. After the solutions were filtered 20 
and pipetted into the nine wells of the depression plate, the 
mineral substrates were deposited into the pre-
crystallization solutions. The depression plates were placed 
and sealed in plastic chambers (Model 156C, Tri State 
Plastics, Dixon, Ky.) that contained 30 ml of precipitating 25 
solution consisting of 5.0 wt % NaCl in high purity water 
(HPLC grade, J. T. Baker Prod. No. 4218-03). The chambers 
were maintained at 18° C. by being immersed in water 
circulating from a constant temperature bath. Protein crys- 30 
tals were recovered from the crystallization solution after 
cessation of crystal growth was observed. Cessation of 
protein crystal growth was generally achieved after seven 
days. 
Crystal Attachment. The degree of attachment between 35 
protein crystals and mineral substrate were visually esti-
mated by microscopy (Nissho Seimitsu Kogaku SS 
microscope, 4x magnification). The percent of crystals 
attached to the mineral substrate was quantified by taking a 
40 
ratio between the number of crystals attached to the sub-
strate to the total number of crystals present in the well. The 
ratio was then multiplied by 100. 
Crystal Analysis. After visual observations were 
performed, all remaining protein solution in each well was 45 
aspirated with a pipette and stored, leaving the crystals 
behind. Next, crystals attached to a mineral substrate as well 
as those not attached to a mineral substrate were washed 
with 5 wt% NaCl, solubilized with 100 µl of HPLC-Grade 
water (J. T. Baker Prod. No. 4218-03) and frozen at -17° C. 50 
Samples selected for purity analysis were removed from 
the freezer and thawed in a water bath containing tap water 
at room temperature. The samples were analyzed by high 
performance liquid chromatography (HPLC) (Shimadzu). 
Samples were passed through a reverse-phase column C18 55 
300 A column (0.9x25 cm) (Rainin). 
Mixtures of lysozyme and ovotransferrin were injected 
into the HPLC to evaluate the separation of peaks achieved 
and determine retention times. It was found that under the 60 
recommended conditions for the C18 300 A column, 
ovotransferrin had a retention time equivalent to that of 
lysozyme. The elution protocol used for separating 
lysozyme and ovotransferrin therefore required refinement 
SOLVENT SYSTEM 
Buffer A: 
Buffer B: 
Flow Rate: 
Temperature of Column: 
Sample injection: 
14 
0.1 % TFA in water 
0.1 % TFA in acetonitrile 
0.75 ml/min. 
Room Temp (23° C.) 
60 µl 
Samples were chromatographed in 60 min. using a linear 
gradient of 17 min. from 15 to 40% buffer B continuing to 
40 min. from 40 to 55% buffer B. Absorbance of the eluate 
was recorded at a wavelength of 230 nm at a detector 
sensitivity of 1 AUFS. (Shimadzu detector). The reproduc-
ibility of the revised protocol was tested by analyzing a 
lysozyme stock solution (50.1 mg/ml) nine successive times. 
The standard deviation of the lysozyme peak area was 0.11 % 
of the mean. Student T-tests at a 95% confidence interval 
were used to examine the data. 
High concentrations of the solubilized recovered crystals 
were injected into the HPLC to determine whether, and to 
what extent, ovotransferrin might be present in the lysozyme 
crystals. From chromatograms it was possible to determine 
the area of the ovotransferrin peak. The mass of ovotrans-
ferrin in the sample was calculated by using a HPLC 
calibration curve. 
Crystal Protein Content. A dye binding spectrophotomet-
ric assay kit (Bio-Rad Protein Assay # 500-0001, Bio-Rad 
Laboratories, Hercules, Calif.) was used to determine the 
total mass of protein present in samples injected into the 
HPLC. The purity of the polypeptide lysozyme was calcu-
lated for this particular experiment as the total protein 
obtained in a sample minus the mass of ovotransferrin in that 
sample, divided by the mass of the total protein in the 
sample, multiplied by 100. 
Statistical analysis of the data was performed by using a 
statistical package (Mini-Tab, Ver. 10.1, Minitab, Inc., State 
College, Pa.). An analysis of variance using a 95% confi-
dence interval was used to examine the data. Additionally, 
two-sample T-tests at a 95% confidence interval were used 
when comparing two observations. 
Results 
Purity of Crystals Attached to Nucleating Agent Com-
pared to Purity of Spontaneously Nucleating Crystals. Crys-
tals obtained from a mixture of lysozyme and ovotransferrin 
(5% of total protein) were removed from the crystallization 
mixture and analyzed for their specific protein content by 
HPLC as described above. The control crystals were 
obtained from crystallization wells that did not contain a 
nucleating agent and therefore were the products of spon-
taneous nucleation. FIG. 1 illustrates that lysozyme crystals 
grown in the presence of and attached to certain nucleating 
agents were significantly higher in purity than control crys-
tals. Lysozyme crystals that spontaneous nucleated averaged 
99.65% in purity whereas lysozyme crystals attached to 
apophyllite, NC-apophyllite, topaz, and magnetite averaged 
at least 99.90% in purity. Lysozyme crystals grown on 
lepidolite, which has an approximate 20% crystal lattice 
mismatch to the crystal lattice of lysozyme, were statisti-
cally equivalent in purity to the control crystals. 
In FIGS. 1-3, the error bars represent the standard error 
obtained by analyzing crystals in three crystallization wells 
for NC-apophyllite and topaz, in four wells for lepidolite, in 
eight wells for magnetite, in fourteen wells for apophyllite, 
and in eighteen wells for the control. In each case, all 
to eliminate ambiguity between peaks of lysozyme and 
ovotransferrin. The refined protocol uses the following con-
ditions: 
65 attached crystals in a well were pooled and analyzed for 
purity and yield. Also, in each case, all non-attached crystals 
in a well were pooled and analyzed for purity and yield. 
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Crystals that were grown in the presence of the exogenous 
nucleating agents but were not attached to those nucleating 
agents did not have as high a purity as those attached to the 
nucleating agent, except for lepidolite. (FIGS. 1 and 2). The 
highest purity of these unattached crystals was always less 5 
than 99.85%. Lysozyme crystals grown in the presence of 
but unattached to the nucleating agent topaz, were signifi-
cantly higher in purity than the control crystals, but these 
crystals were still significantly lower in purity than 
lysozyme crystals attached to the same nucleating agent. 10 
Additionally, the lysozyme crystals grown in the presence of 
and attached to an exogenous mineral nucleating agent with 
a close lattice match to the lattice of lysozyme were always 
of a higher purity than those crystals unattached to the same 
mineral nucleating agent and of the control. 15 
These unattached crystals result from spontaneous nucle-
ation and were generally equivalent in purity to the control 
crystals. Experiments have shown that the unattached crys-
tals were not the result of small nucleating agents that 
originated from the exogenous nucleating agent through 20 
mechanical disturbance, small material sloughed off from 
the exogenous nucleating agent, or from any nucleating 
agent accidentally added to the crystallization well. 
Crystal Yields. The amount of protein recovered from the 
crystallization mixture was highly correlated to the dimen- 25 
sion differences between the crystal lattice of the nucleating 
agent and the crystal lattice of lysozyme. (FIG. 3). Lepido-
lite and magnetite, those mineral nucleating agents with the 
least lattice match to lysozyme, exhibited much lower yields 
of attached lysozyme crystals than the other nucleating 30 
agents with a closer lattice match. 
The crystallization yield in the presence of an exogenous 
nucleating agent is the total mass of polypeptide crystal 
obtained from the crystallization procedure that is attached 
to the nucleating agent over the total mass of polypeptide in 35 
the crystallization mixture. The crystallization yield without 
an exogenous nucleating agent is the total mass of crystal-
lized polypeptide over the total mass of polypeptide in the 
crystallization mixture. The term "high yield" then relates to 
a comparison of these two yields. For example, the control 40 
yield minus the yield for crystals attached to an exogenous 
nucleating agent multiplied by 100 and then divided by the 
control yield gives a yield of the crystals attached to the 
nucleating agent as a percent deviation from the control 
yield. Here, the term "high yield" applies to a polypeptide 45 
crystallization in the presence of an exogenous nucleating 
agent where this percent deviation relative to the control is 
less than 22%. The calculated percent yield deviations 
relative to the control in this experiment were 13, 26, 18, 51, 
and 41, for the exogenous nucleating agents apophyllite, 50 
NC-apophyllite, topaz, lepidolite, and magnetite, respect-
fully. The only nucleating agents that exhibited a high yield 
of the high purity polypeptide crystals (those crystals 
attached to the nucleating agent) were apophyllite and topaz, 
both of which are within the areal lattice match parameter of 55 
at least 85%. Those nucleating agents with an areal lattice 
match below 85% did not exhibit a high yield of high purity 
polypeptide crystals. 
Throughout this application, various publications are ref-
erenced. The disclosures of these publications in their entire- 60 
ties are hereby incorporated by reference into this applica-
tion in order to more fully describe the state of the art to 
which this invention pertains. 
It will be apparent to those skilled in the art that various 
modifications and variations can be made in the present 65 
invention without departing from the scope or spirit of the 
invention. Other embodiments of the invention will be 
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apparent to those skilled in the art from consideration of the 
specification and practice of the invention disclosed herein. 
It is intended that the specification and example be consid-
ered as exemplary only, with a true scope and spirit of the 
invention being indicated by the following claims. 
What is claimed is: 
1. A method of highly purifying a polypeptide from a 
contaminant by crystallization comprising: 
(a) contacting a mixture containing uncrystallized 
polypeptides and a contaminant with an exogenous 
nucleating agent that has an areal lattice match of at 
least 90.4% to the polypeptide, 
(b) crystallizing the polypeptides, thereby forming at least 
one crystal of the polypeptide attached to the nucleating 
agent, the attached crystal being of a high purity, and at 
least one polypeptide crystal unattached to the nucle-
ating agent, the unattached crystal being of a lower 
purity than the attached crystal, and 
( c) separating the crystal attached to the nucleating agent 
from the crystal unattached to the nucleating agent. 
2. A method of purifying a polypeptide in a high purity 
and in a high yield from a contaminant by crystallization 
comprising: 
(a) contacting a mixture containing uncrystallized 
polypeptides and a contaminant with an exogenous 
nucleating agent that has an areal lattice match of at 
least 90.4% to the polypeptide, 
(b) crystallizing the polypeptides, thereby forming at least 
one crystal of the polypeptide attached to the nucleating 
agent, the attached crystal being of a high purity and 
produced in a high yield, and at least one crystal 
unattached to the nucleating agent, the unattached 
crystal being of a lower purity than the attached crystal, 
and 
( c) separating the crystal attached to the nucleating agent 
from the crystal unattached to the nucleating agent. 
3. The method of claim 1, wherein the separation in step 
( c) comprises separating a plurality of crystals attached to 
the nucleating agent from the crystal unattached to the 
nucleating agent. 
4. The method of claim 2, wherein the separation in step 
( c) comprises separating a plurality of crystals attached to 
the nucleating agent from the crystal unattached to the 
nucleating agent. 
5. The method of claim 1, wherein the separation in step 
(c) comprises separating a majority of the crystals attached 
to the nucleating agent from the crystal unattached to the 
nucleating agent. 
6. The method of claim 2, wherein the separation in step 
(c) comprises separating a majority of the crystals attached 
to the nucleating agent from the crystal unattached to the 
nucleating agent. 
7. The method of claim 1, wherein the crystallization step 
(b) comprises increasing the concentration of the polypep-
tide in the mixture. 
8. The method of claim 1, wherein the crystallization step 
(b) comprises decreasing the temperature of the mixture 
containing the polypeptide and the contaminants. 
9. The method of claim 2, wherein the crystallization step 
(b) comprises increasing the concentration of the polypep-
tide in the mixture. 
10. The method of claim 2, wherein the crystallization 
step (b) comprises decreasing the temperature of the mixture 
containing the polypeptide and the contaminants. 
11. The method of claim 1, wherein the separation step (c) 
comprises a separation by hand, by magnetic separation, by 
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density separation, or by removing a solid support from the 
mixture to which the nucleating agent with its attached 
crystal is attached. 
12. The method of claim 2, wherein the separation step (c) 
comprises a separation by hand, by magnetic separation, by 5 
density separation, or by removing a solid support from the 
mixture to which the nucleating agent with its attached 
crystal is attached. 
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crystal is at least 99.85%, and wherein the polypeptide is not 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
28. A composition consisting essentially of a polypeptide 
crystal which was crystallized by contacting the polypeptide 
to an exogenous nucleating agent that has an areal lattice 
match of at least 90.4% to the polypeptide and that has been 
separated from the nucleating agent, wherein the purity of 
the crystal is at least 99.85%, and wherein the polypeptide 
is not lysozyme, canavalin, concanavalin B, or beef liver 13. The method of claim 1, wherein the nucleating agent 
is a mineral. 10 catalase. 29. A composition comprising a polypeptide crystal which 
was crystallized by contacting the polypeptide to an exog-
enous nucleating agent that has an areal lattice match of at 
least 90.4% to the polypeptide and that has been separated 
from the nucleating agent, wherein the purity of the crystal 
14. The method of claim 2, wherein the nucleating agent 
is a mineral. 
15. The method of claim 1, further comprising separating 
the polypeptide crystal attached to the nucleating agent from 
the nucleating agent. 
16. The method of claim 2, further comprising separating 
the polypeptide crystal attached to the nucleating agent from 
the nucleating agent. 
15 is at least 99.85%, and wherein the polypeptide is not 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
17. The method of claim 15, wherein the crystal attached 
to the nucleating agent is separated from the nucleating 20 
agent by shearing the crystal from the nucleating agent. 
18. The method of claim 15, wherein the crystal attached 
to the nucleating agent is separated from the nucleating 
agent by detaching the crystal from the nucleating agent by 
solubilizing the crystal and then separating the detached 25 
nucleating agent from the polypeptide. 
19. The method of claim 16, wherein the crystal attached 
to the nucleating agent is separated from the nucleating 
agent by shearing the crystal from the nucleating agent. 
20. The method of claim 16, wherein the crystal attached 30 
to the nucleating agent is separated from the nucleating 
agent by detaching the crystal from the nucleating agent by 
solubilizing the crystal and then separating the detached 
nucleating agent from the polypeptide. 
21. A composition consisting of at least one polypeptide 35 
crystal attached to an exogenous nucleating agent, wherein 
the polypeptide was crystallized by contacting the polypep-
tide with the exogenous nucleating agent, wherein the exog-
enous nucleating agent has an areal lattice match of at least 
90.4% to the polypeptide, and wherein the polypeptide is not 40 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
22. A composition consisting essentially of at least one 
polypeptide crystal attached to an exogenous nucleating 
agent, wherein the polypeptide was crystallized by contact-
ing the polypeptide with the exogenous nucleating agent, 45 
wherein the exogenous nucleating agent has an areal lattice 
match of at least 90.4% to the polypeptide, and wherein the 
polypeptide is not lysozyme, canavalin, concanavalin B, or 
beef liver catalase. 
23. A composition comprising at least one polypeptide 50 
crystal attached to an exogenous nucleating agent, wherein 
the polypeptide was crystallized by contacting the polypep-
tide with the exogenous nucleating agent, wherein the exog-
enous nucleating agent has an areal lattice match of at least 
90.4% to the polypeptide, and wherein the polypeptide is not 55 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
24. The composition of claim 21, wherein the purity of the 
crystal is at least 99 .85%. 
25. The composition of claim 22, wherein the purity of the 
crystal is at least 99 .85%. 
26. The composition of claim 23, wherein the purity of the 
crystal is at least 99 .85%. 
60 
27. A composition consisting of a polypeptide crystal 
which was crystallized by contacting the polypeptide to an 
exogenous nucleating agent that has an areal lattice match of 65 
at least 90.4% to the polmpeptide and that has been sepa-
rated from the nucleating agent, wherein the purity of the 
30. A composition consisting of a polypeptide which was 
crystallized by contacting the polypeptide to an exogenous 
nucleating agent that has an areal lattice match of at least 
90.4% to the polypeptide and that has been separated from 
the nucleating agent, wherein the purity of the crystal is at 
least 99.85%, and wherein the polypeptide is not lysozyme, 
canavalin, concanavalin B, or beef liver catalase. 
31. A composition consisting essentially of a polypeptide 
which was crystallized by contacting the polypeptide to an 
exogenous nucleating agent that has an areal lattice match of 
at least 90.4% to the polypeptide and that has been separated 
from the nucleating agent, wherein the purity of the crystal 
is at least 99.85%, and wherein the polypeptide is not 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
32. A composition comprising a polypeptide which was 
crystallized by contacting the polypeptide to an exogenous 
nucleating agent that has an areal lattice match of at least 
90.4% to the polypeptide and that has been separated from 
the nucleating agent, wherein the purity of the crystal is at 
least 99.85%, and wherein the polypeptide is not lysozyme, 
canavalin, concanavalin B, or beef liver catalase. 
33. A highly purified polypeptide crystal obtained by the 
method of claim 1. 
34. A highly purified polypeptide crystal obtained by the 
method of claim 2. 
35. A highly purified polypeptide crystal obtained by the 
method of claim 19. 
36. A highly purified polypeptide crystal obtained by the 
method of claim 20. 
37. The method of claim 1, wherein the polypeptide is not 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
38. The method of claim 2, wherein the polypeptide is not 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
39. A method of highly purifying a biological compound 
from a contaminant by crystallization comprising: 
(a) contacting a mixture containing uncrystallized bio-
logical compounds and a contaminant with an exog-
enous nucleating agent that has an areal lattice match of 
at least 90.4% to the biological compound, 
(b) crystallizing the biological compounds, thereby form-
ing at least one crystal of the biological compound 
attached to the nucleating agent, the attached crystal 
being of a high purity, and at least one biological 
compound crystal unattached to the nucleating agent, 
the unattached crystal being of a lower purity than the 
attached crystal, and 
( c) separating the crystal attached to the nucleating agent 
from the crystal unattached to the nucleating agent. 
40. A method of purifying a biological compound in a 
high purity and in a high yield from a contaminant by 
crystallization comprising: 
5,869,604 
19 
(a) contacting a mixture containing uncrystallized bio-
logical compounds and a contaminant with an exog-
enous nucleating agent that has an areal lattice match of 
at least 90.4% to the biological compound, 
(b) crystallizing the biological compounds, thereby form- 5 
ing at least one crystal of the biological compound 
attached to the nucleating agent, the attached crystal 
being of a high purity and produced in a high yield, and 
at least one crystal unattached to the nucleating agent, 
the unattached crystal being of a lower purity than the 10 
attached crystal, and 
( c) separating the crystal attached to the nucleating agent 
from the crystal unattached to the nucleating agent. 
41. A composition comprising at least one biological 
compound crystal attached to an exogenous nucleating 15 
agent, wherein the biological compound was crystallized by 
contacting the biological compound with the exogenous 
nucleating agent, wherein the exogenous nucleating agent 
has an areal lattice match of at least 90.4% to the biological 
compound, and wherein the biological compound is not 20 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
20 
42. A composition compnsmg a biological compound 
crystal which was crystallized by contacting the biological 
compound to an exogenous nucleating agent that has an 
areal lattice match of at least 90.4% to the biological 
compound and that has been separated from the nucleating 
agent, wherein the purity of the crystal is at least 99.85%, 
and wherein the biological compound is not lysozyme, 
canavalin, concanavalin B, or beef liver catalase. 
43. A composition comprising a biological compound 
which was crystallized by contacting the biological com-
pound to an exogenous nucleating agent that has an areal 
lattice match of at least 90.4% to the biological compound 
and that has been separated from the nucleating agent, 
wherein the purity of the biological compound is at least 
99.85%, and wherein the biological compound is not 
lysozyme, canavalin, concanavalin B, or beef liver catalase. 
44. The method of claim 1, wherein the exogenous 
nucleating agent has a lattice match of at least 99.60%. 
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